JP2006518372A5 - - Google Patents

Download PDF

Info

Publication number
JP2006518372A5
JP2006518372A5 JP2006502491A JP2006502491A JP2006518372A5 JP 2006518372 A5 JP2006518372 A5 JP 2006518372A5 JP 2006502491 A JP2006502491 A JP 2006502491A JP 2006502491 A JP2006502491 A JP 2006502491A JP 2006518372 A5 JP2006518372 A5 JP 2006518372A5
Authority
JP
Japan
Prior art keywords
meganuclease
use according
dna
sequence
site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006502491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006518372A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/000848 external-priority patent/WO2004067753A2/en
Publication of JP2006518372A publication Critical patent/JP2006518372A/ja
Publication of JP2006518372A5 publication Critical patent/JP2006518372A5/ja
Pending legal-status Critical Current

Links

JP2006502491A 2003-01-28 2004-01-28 脊椎動物の体組織においてエクスビボかつイントトで相同的組換えを誘発するためのメガヌクレアーゼの使用およびその応用 Pending JP2006518372A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44291103P 2003-01-28 2003-01-28
US49153503P 2003-08-01 2003-08-01
PCT/IB2004/000848 WO2004067753A2 (en) 2003-01-28 2004-01-28 Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.

Publications (2)

Publication Number Publication Date
JP2006518372A JP2006518372A (ja) 2006-08-10
JP2006518372A5 true JP2006518372A5 (enExample) 2007-03-01

Family

ID=32829807

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006502491A Pending JP2006518372A (ja) 2003-01-28 2004-01-28 脊椎動物の体組織においてエクスビボかつイントトで相同的組換えを誘発するためのメガヌクレアーゼの使用およびその応用
JP2006502490A Expired - Lifetime JP4966006B2 (ja) 2003-01-28 2004-01-28 カスタムメイドメガヌクレアーゼおよびその使用
JP2011242304A Pending JP2012085640A (ja) 2003-01-28 2011-11-04 カスタムメイドメガヌクレアーゼおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2006502490A Expired - Lifetime JP4966006B2 (ja) 2003-01-28 2004-01-28 カスタムメイドメガヌクレアーゼおよびその使用
JP2011242304A Pending JP2012085640A (ja) 2003-01-28 2011-11-04 カスタムメイドメガヌクレアーゼおよびその使用

Country Status (6)

Country Link
US (16) US20060206949A1 (enExample)
EP (5) EP1590468A2 (enExample)
JP (3) JP2006518372A (enExample)
AU (3) AU2004208031B2 (enExample)
CA (2) CA2514417A1 (enExample)
WO (2) WO2004067753A2 (enExample)

Families Citing this family (362)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009095742A1 (en) * 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
US8206965B2 (en) * 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
US20100151556A1 (en) * 2002-03-15 2010-06-17 Cellectis Hybrid and single chain meganucleases and use thereof
WO2004067753A2 (en) 2003-01-28 2004-08-12 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
ES2808687T3 (es) * 2003-08-08 2021-03-01 Sangamo Therapeutics Inc Métodos y composiciones para escisión dirigida y recombinación
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
WO2007034262A1 (en) * 2005-09-19 2007-03-29 Cellectis Heterodimeric meganucleases and use thereof
WO2006097784A1 (en) * 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
ES2347684T3 (es) * 2005-03-15 2010-11-03 Cellectis Variantes de la meganucleasa i-crei con especificidad modifica, metodo de preparacion y usos de las mismas.
CN101155921B (zh) 2005-04-04 2013-02-06 拜尔作物科学公司 用于去除所选择dna序列的方法和手段
CA2626262C (en) 2005-10-18 2015-09-08 Homme W. Hellinga Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
US20140010797A1 (en) * 2005-10-18 2014-01-09 Duke University Fusion Molecules of Rationally-Designed DNA-Binding Proteins and Effector Domains
WO2007049095A1 (en) * 2005-10-25 2007-05-03 Cellectis Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof
WO2007060495A1 (en) 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
WO2007093836A1 (en) 2006-02-13 2007-08-23 Cellectis Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof
US10407672B2 (en) * 2006-03-27 2019-09-10 Seattle Children's Hospital Compositions and methods comprising the use of cell surface displayed homing endonucleases
EP2019839B1 (en) * 2006-05-25 2011-12-07 Sangamo BioSciences, Inc. Methods and compositions for gene inactivation
WO2008010009A1 (en) * 2006-07-18 2008-01-24 Cellectis Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof
US8367890B2 (en) 2006-09-28 2013-02-05 Bayer Cropscience N.V. Methods and means for removal of a selected DNA sequence
BRPI0718747A2 (pt) * 2006-11-14 2013-12-03 Cellectis Variantes meganuclease que clavam uma ou sequência alvo de dna a partir do gene hprt e usos das mesmas.
WO2008059317A1 (en) * 2006-11-14 2008-05-22 Cellectis Meganuclease variants cleaving a dna target sequence from the hprt gene and uses thereof
EP2086644A2 (en) * 2006-11-17 2009-08-12 Schering Corporation Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders
WO2008093152A1 (en) * 2007-02-01 2008-08-07 Cellectis Obligate heterodimer meganucleases and uses thereof
CN101679959A (zh) * 2007-02-19 2010-03-24 赛莱克蒂斯公司 具有新的底物特异性的laglidadg归巢核酸内切酶变体及其用途
WO2008102199A1 (en) * 2007-02-20 2008-08-28 Cellectis Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof
US20100235929A1 (en) * 2007-06-01 2010-09-16 Buelow Research Enterprises Llc Compositions and Methods for Producing Antibodies Having Human Idiotypes in Transgenic Birds
CN104212844A (zh) * 2007-06-01 2014-12-17 索拉兹米公司 在微生物中生产油
KR102096731B1 (ko) * 2007-06-01 2020-04-02 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
US8765448B2 (en) 2007-06-05 2014-07-01 Bayer CropScience, N.V. Methods and means for exact replacement of target DNA in eukaryotic organisms
CN101784658A (zh) * 2007-06-06 2010-07-21 赛莱克蒂斯公司 增强来自I-CreI的大范围核酸酶的切割活性的方法
WO2009006297A2 (en) 2007-06-29 2009-01-08 Pioneer Hi-Bred International, Inc. Methods for altering the genome of a monocot plant cell
WO2009013559A1 (en) 2007-07-23 2009-01-29 Cellectis Meganuclease variants cleaving a dna target sequence from the human hemoglobin beta gene and uses thereof
WO2009019528A1 (en) * 2007-08-03 2009-02-12 Cellectis Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
CN101883863B (zh) * 2007-09-27 2018-01-23 桑格摩生物科学股份有限公司 生物活性核酸酶的快速体内鉴定
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
EP3578646A3 (en) 2007-10-31 2020-03-18 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
AU2008335324A1 (en) * 2007-12-07 2009-06-18 Precision Biosciences, Inc. Rationally-designed meganucleases with recognition sequences found in DNase hypersensitive regions of the human genome
WO2009074842A1 (en) * 2007-12-13 2009-06-18 Cellectis Improved chimeric meganuclease enzymes and uses thereof
AP2967A (en) 2008-02-29 2014-09-30 Monsanto Technology Llc Zea mays plant event MON87460 and compositions andmethods for detection thereof
WO2009114321A2 (en) 2008-03-11 2009-09-17 Precision Biosciencs, Inc. Rationally-designed meganucleases for maize genome engineering
US20100071083A1 (en) * 2008-03-12 2010-03-18 Smith James J Temperature-dependent meganuclease activity
WO2009146179A1 (en) * 2008-04-15 2009-12-03 University Of Iowa Research Foundation Zinc finger nuclease for the cftr gene and methods of use thereof
EP2279250A4 (en) * 2008-04-28 2011-10-12 Prec Biosciences Inc Fusion Molecules of DNA Binding Proteins with Rational Design and Effects Domain
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
EP3495478A3 (en) 2008-07-14 2019-07-24 Precision Biosciences, Inc. Recognition sequences for i-crei-derived meganucleases and uses thereof
CA2736336A1 (en) * 2008-09-08 2010-03-11 Cellectis Meganuclease variants cleaving a dna target sequence from a glutamine synthetase gene and uses thereof
EP2180058A1 (en) 2008-10-23 2010-04-28 Cellectis Meganuclease recombination system
CN102712858B (zh) * 2008-11-28 2015-08-12 索拉兹米公司 在重组异养型微生物中制备特制油
US20110016541A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of sensory-related genes in animals
US20110023154A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Silkworm genome editing with zinc finger nucleases
US20110030072A1 (en) * 2008-12-04 2011-02-03 Sigma-Aldrich Co. Genome editing of immunodeficiency genes in animals
US20110023144A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in amyotrophyic lateral sclerosis disease
US20110023150A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of genes associated with schizophrenia in animals
US20110023158A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Bovine genome editing with zinc finger nucleases
US20110023152A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of cognition related genes in animals
US20110023145A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in autism spectrum disorders
US20110023143A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of neurodevelopmental genes in animals
US20110023148A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of addiction-related genes in animals
US20110023153A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in alzheimer's disease
US20110023140A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Rabbit genome editing with zinc finger nucleases
US20110016540A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of genes associated with trinucleotide repeat expansion disorders in animals
US20110023156A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Feline genome editing with zinc finger nucleases
US20110016539A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of neurotransmission-related genes in animals
US20110016543A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
US20110023151A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of abc transporters
US20110023147A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of prion disorder-related genes in animals
US20110023139A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in cardiovascular disease
US20110023141A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved with parkinson's disease
US20110023146A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in secretase-associated disorders
US20110023149A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in tumor suppression in animals
US20110016546A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Porcine genome editing with zinc finger nucleases
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
WO2010093966A2 (en) * 2009-02-12 2010-08-19 Fred Hutchinson Cancer Research Center Generation of a dna nicking enzyme that stimulates site-specific gene conversion from a homing endonuclease
AU2010226313B2 (en) 2009-03-20 2014-10-09 Sangamo Therapeutics, Inc. Modification of CXCR4 using engineered zinc finger proteins
WO2010122367A2 (en) * 2009-04-21 2010-10-28 Cellectis Meganuclease variants cleaving the genomic insertion of a virus and uses thereof
US8772008B2 (en) * 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
WO2010136841A2 (en) * 2009-05-26 2010-12-02 Cellectis Meganuclease variants cleaving the genome of a non-genomically integrating virus and uses thereof
EP2435560A2 (en) 2009-05-26 2012-04-04 Cellectis Meganuclease variants cleaving the genome of a pathogenic non-integrating virus and uses thereof
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
WO2011002503A1 (en) 2009-06-30 2011-01-06 Sangamo Biosciences, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
WO2011007193A1 (en) 2009-07-17 2011-01-20 Cellectis Viral vectors encoding a dna repair matrix and containing a virion-associated site specific meganuclease for gene targeting
US9234016B2 (en) 2009-07-28 2016-01-12 Sangamo Biosciences, Inc. Engineered zinc finger proteins for treating trinucleotide repeat disorders
EP3428289B1 (en) * 2009-08-11 2020-05-20 Sangamo Therapeutics, Inc. Organisms homozygous for targeted modification
WO2011021062A1 (en) * 2009-08-21 2011-02-24 Cellectis Meganuclease variants cleaving a dna target sequence from the human lysosomal acid alpha-glucosidase gene and uses thereof
WO2011036640A2 (en) 2009-09-24 2011-03-31 Cellectis Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
CN102639695B (zh) 2009-10-26 2015-01-21 独立行政法人农业生物资源研究所 转基因植物细胞的制造方法
EP3456826B1 (en) * 2009-12-10 2023-06-28 Regents of the University of Minnesota Tal effector-mediated dna modification
AU2010339481B2 (en) 2009-12-30 2016-02-04 Pioneer Hi-Bred International, Inc. Methods and compositions for targeted polynucleotide modification
US20120329067A1 (en) * 2010-01-22 2012-12-27 Barbas Iii Carlos F Methods of Generating Zinc Finger Nucleases Having Altered Activity
EP2531609A1 (en) 2010-02-02 2012-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and therapy of retinitis pigmentosa
US10143186B2 (en) 2010-02-08 2018-12-04 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
WO2011101696A1 (en) 2010-02-18 2011-08-25 Cellectis Improved meganuclease recombination system
EP2539445B1 (en) 2010-02-26 2018-03-21 Cellectis Use of endonucleases for inserting transgenes into safe harbor loci
WO2011117249A1 (en) 2010-03-22 2011-09-29 Philip Morris Products S.A. Modifying enzyme activity in plants
EP2561075B1 (en) 2010-04-23 2018-06-27 University of Massachusetts Aav-based treatment of cholesterol-related disorders
DK2826860T3 (en) 2010-04-23 2018-12-03 Univ Massachusetts CNS targeting AAV vectors and methods for their use
CA2833905C (en) 2010-04-23 2019-09-10 University Of Massachusetts Multicistronic expression constructs
EP2569435A1 (en) * 2010-05-12 2013-03-20 Cellectis Meganuclease variants cleaving a dna target sequence from the rhodopsin gene and uses thereof
WO2011141820A1 (en) 2010-05-12 2011-11-17 Cellectis Meganuclease variants cleaving a dna target sequence from the dystrophin gene and uses thereof
JP6208580B2 (ja) 2010-05-17 2017-10-04 サンガモ セラピューティクス, インコーポレイテッド 新規のdna結合タンパク質及びその使用
CN106135460B (zh) 2010-05-28 2020-07-24 柯碧恩生物技术公司 包含特制油的食品组合物
WO2011156430A2 (en) * 2010-06-07 2011-12-15 Fred Hutchinson Cancer Research Center Generation and expression of engineered i-onui endonuclease and its homologues and uses thereof
RU2639512C2 (ru) 2010-06-09 2017-12-21 Байер Кропсайенс Нв Способы и средство модификации растительного генома в нуклеотидной последовательности, широко используемой в геномной инженерии растений
AU2011264074B2 (en) 2010-06-09 2015-01-22 Bayer Cropscience Nv Methods and means to modify a plant genome at a nucleotide sequence commonly used in plant genome engineering
GB201009732D0 (en) 2010-06-10 2010-07-21 Gene Bridges Gmbh Direct cloning
CA2802822A1 (en) 2010-06-15 2012-01-05 Cellectis Method for improving cleavage of dna by endonuclease sensitive to methylation
SG186932A1 (en) 2010-07-07 2013-02-28 Cellectis Meganucleases variants cleaving a dna target sequence in the nanog gene and uses thereof
WO2012010976A2 (en) 2010-07-15 2012-01-26 Cellectis Meganuclease variants cleaving a dna target sequence in the tert gene and uses thereof
WO2012007848A2 (en) 2010-07-16 2012-01-19 Cellectis Meganuclease variants cleaving a dna target sequence in the was gene and uses thereof
EP2412806B1 (en) * 2010-07-28 2014-01-08 Institut Pasteur Use of terminal deoxynucleotidyl transferase for mutagenic DNA repair to generate variability, at a determined position in DNA
US9187762B2 (en) 2010-08-13 2015-11-17 Pioneer Hi-Bred International, Inc. Compositions and methods comprising sequences having hydroxyphenylpyruvate dioxygenase (HPPD) activity
EP2633040B1 (en) 2010-10-27 2019-07-10 Cellectis Method for increasing the efficiency of double-strand break-induced mutagenesis
CA2816125C (en) 2010-11-03 2018-12-11 Solazyme, Inc. Microbial oils with lowered pour points, dielectric fluids produced therefrom, and related methods
CA2825691C (en) 2011-02-02 2020-08-25 Solazyme, Inc. Tailored oils produced from recombinant oleaginous microorganisms
US9044492B2 (en) 2011-02-04 2015-06-02 Cellectis Sa Method for modulating the efficiency of double-strand break-induced mutagenesis
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
EP2680877B1 (en) 2011-02-28 2019-07-10 Seattle Children's Research Institute Coupling endonucleases with end-processing enzymes drive high efficiency gene disruption
BR112013024337A2 (pt) 2011-03-23 2017-09-26 Du Pont locus de traço transgênico complexo em uma planta, planta ou semente, método para produzir em uma planta um locus de traço transgênico complexo e construto de expressão
CA3111953C (en) 2011-04-05 2023-10-24 Cellectis Method for the generation of compact tale-nucleases and uses thereof
WO2012138901A1 (en) 2011-04-05 2012-10-11 Cellectis Sa Method for enhancing rare-cutting endonuclease efficiency and uses thereof
EP3318634A1 (en) 2011-04-21 2018-05-09 University of Massachusetts Raav-based compositions and methods for treating diseases involving dominant-negative or gain of function mutations
WO2012149470A1 (en) 2011-04-27 2012-11-01 Amyris, Inc. Methods for genomic modification
BR112013028306B1 (pt) 2011-05-02 2020-04-07 Univ Nebraska plantas com características úteis e processos relacionados
EP2705138B1 (en) 2011-05-06 2017-03-22 TerraVia Holdings, Inc. Genetically engineered microorganisms that metabolize xylose
WO2012158778A1 (en) 2011-05-16 2012-11-22 Cellectis S.A. Doubly secure transgenic algae or cyanobacteria strains to prevent their establishment and spread in natural ecosystems
WO2012167192A2 (en) * 2011-06-01 2012-12-06 Precision Biosciences, Inc. Methods and products for producing engineered mammalian cell lines with amplified transgenes
WO2013009525A1 (en) 2011-07-08 2013-01-17 Cellectis S.A. Method for increasing the efficiency of double-strand break-induced mutagenssis
WO2013016446A2 (en) * 2011-07-25 2013-01-31 Sangamo Biosciences, Inc. Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
HRP20192255T1 (hr) 2011-08-05 2020-03-06 Regeneron Pharmaceuticals, Inc. Humanizirani miševi s univerzalnim lakim lancem
CN107287234A (zh) 2011-08-22 2017-10-24 拜尔作物科学公司 修饰植物基因组的方法和手段
US20140283819A1 (en) 2011-10-12 2014-09-25 Bayer Cropscience Ag Plants with decreased activity of a starch dephosphorylating enzyme
US20140251317A1 (en) 2011-10-12 2014-09-11 Bayer Cropscience Ag Plants with decreased activity of a starch dephosphorylating enzyme
CA2852955C (en) * 2011-10-27 2021-02-16 Sangamo Biosciences, Inc. Methods and compositions for modification of the hprt locus
MX2014008243A (es) 2012-01-06 2015-02-20 Pioner Hi Bred International Inc Un metodo para seleccionar plantas por elementos geneticos que inducen la partenogenesis en plantas.
CN104284669A (zh) 2012-02-24 2015-01-14 弗雷德哈钦森癌症研究中心 治疗血红蛋白病的组合物和方法
NZ629427A (en) 2012-02-29 2016-04-29 Sangamo Biosciences Inc Methods and compositions for treating huntington’s disease
EP3141259B1 (en) 2012-03-15 2019-07-31 Cellectis Repeat variable diresidues for targeting nucleotides
DK2828384T3 (en) 2012-03-23 2018-07-16 Cellectis PROCEDURE FOR SURVIVING SENSITIVITY TO CHEMICAL DNA MODIFICATIONS OF CONSTRUCTED SPEECH DNA BINDING DOMAINS
US9719114B2 (en) 2012-04-18 2017-08-01 Terravia Holdings, Inc. Tailored oils
AU2013249172C1 (en) 2012-04-18 2017-08-10 Corbion Biotech, Inc. Tailored oils
US11518997B2 (en) 2012-04-23 2022-12-06 BASF Agricultural Solutions Seed US LLC Targeted genome engineering in plants
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
WO2013182910A2 (en) 2012-06-05 2013-12-12 Cellectis New transcription activator-like effector (tale) fusion protein
EP2861737B1 (en) 2012-06-19 2019-04-17 Regents Of The University Of Minnesota Gene targeting in plants using dna viruses
US10648001B2 (en) * 2012-07-11 2020-05-12 Sangamo Therapeutics, Inc. Method of treating mucopolysaccharidosis type I or II
HUE051612T2 (hu) * 2012-07-11 2021-03-01 Sangamo Therapeutics Inc Eljárások és készítmények lizoszomális tárolási betegségek kezelésére
WO2014018601A2 (en) 2012-07-24 2014-01-30 Cellectis New modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins
WO2014027615A1 (ja) * 2012-08-16 2014-02-20 公立大学法人横浜市立大学 ミトコンドリア複合体iii欠乏症患者又は保因者の検出方法
WO2014033556A2 (en) 2012-09-03 2014-03-06 Cellectis Methods for modulating tal specificity
AU2013312838B2 (en) 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof
AU2013329186B2 (en) 2012-10-10 2019-02-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
BR112015009812A2 (pt) 2012-10-31 2017-08-22 Cellectis Método para a inserção genética específica em um genoma de planta, célula de planta transformada e seu uso, planta resistente a herbicidas, kit, vetor, e célula hospedeira
CN104968193B (zh) 2012-11-01 2021-02-09 塞尔克蒂斯股份有限公司 用于生成治疗性蛋白质的植物
EP2925779A1 (en) 2012-11-30 2015-10-07 Institut Pasteur Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock
US20140178561A1 (en) 2012-12-21 2014-06-26 Cellectis Potatoes with reduced cold-induced sweetening
DK2938184T3 (en) 2012-12-27 2018-12-17 Keygene Nv Method of removing a genetic linkage in a plant
US9279058B2 (en) 2013-01-11 2016-03-08 Floor Iptech Ab Digital embossing
WO2014118719A1 (en) 2013-02-01 2014-08-07 Cellectis Tevl chimeric endonuclease and their preferential cleavage sites
WO2014128659A1 (en) 2013-02-21 2014-08-28 Cellectis Method to counter-select cells or organisms by linking loci to nuclease components
WO2014158593A1 (en) * 2013-03-13 2014-10-02 President And Fellows Of Harvard College Mutants of cre recombinase
US10113162B2 (en) * 2013-03-15 2018-10-30 Cellectis Modifying soybean oil composition through targeted knockout of the FAD2-1A/1B genes
JP6591898B2 (ja) * 2013-03-15 2019-10-16 セレクティス Fad2−1a/1b遺伝子の標的化ノックアウトを介した、大豆油組成物の改変
RU2725542C2 (ru) 2013-05-13 2020-07-02 Селлектис Способы конструирования высокоактивных т-клеток для иммунотерапии
AU2014279694B2 (en) 2013-06-14 2020-07-23 Cellectis Methods for non-transgenic genome editing in plants
MX363842B (es) 2013-08-22 2019-04-05 Du Pont Métodos para producir modificaciones genéticas en un genoma vegetal sin incorporar un marcador transgénico seleccionable, y composiciones de éstas.
US10767188B2 (en) 2013-09-25 2020-09-08 Nutech Ventures Methods and compositions for obtaining useful plant traits
CA2925527A1 (en) 2013-10-04 2015-04-09 Solazyme, Inc. Tailored oils
AU2014338910B2 (en) 2013-10-25 2020-12-10 Cellectis Design of rare-cutting endonucleases for efficient and specific targeting DNA sequences comprising highly repetitive motives
NZ719477A (en) 2013-11-11 2022-05-27 Sangamo Therapeutics Inc Methods and compositions for treating huntington’s disease
EP3083958B1 (en) 2013-12-19 2019-04-17 Amyris, Inc. Methods for genomic integration
SG11201605046YA (en) 2013-12-20 2016-07-28 Hutchinson Fred Cancer Res Tagged chimeric effector molecules and receptors thereof
AU2015229299A1 (en) * 2014-03-12 2016-09-22 Precision Biosciences, Inc. Dystrophin gene exon deletion using engineered nucleases
AU2015231294B2 (en) 2014-03-18 2020-10-29 University Of Massachusetts rAAV-based compositions and methods for treating amyotrophic lateral sclerosis
ES2879373T3 (es) 2014-03-18 2021-11-22 Sangamo Therapeutics Inc Métodos y composiciones para la regulación de la expresión de proteínas de dedo de zinc
CN106460009A (zh) 2014-03-21 2017-02-22 小利兰·斯坦福大学托管委员会 无核酸酶的基因组编辑
SG10201808225TA (en) 2014-03-21 2018-10-30 Regeneron Pharma Non-human animals that make single domain binding proteins
WO2015187825A2 (en) 2014-06-03 2015-12-10 University Of Massachusetts Compositions and methods for modulating dysferlin expression
WO2015193858A1 (en) 2014-06-20 2015-12-23 Cellectis Potatoes with reduced granule-bound starch synthase
US9969990B2 (en) 2014-07-10 2018-05-15 Corbion Biotech, Inc. Ketoacyl ACP synthase genes and uses thereof
WO2016054554A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs
EP3795580A1 (en) 2014-10-03 2021-03-24 University of Massachusetts High efficiency library-identified aav vectors
WO2016065001A1 (en) 2014-10-21 2016-04-28 University Of Massachusetts Recombinant aav variants and uses thereof
CA2971517A1 (en) 2014-12-19 2016-06-23 Universite De Nantes Anti il-34 antibodies
CA2975709A1 (en) 2015-02-02 2016-08-11 Cellectis Agrobacterium-mediated genome modification without t-dna integration
US10584321B2 (en) 2015-02-13 2020-03-10 University Of Massachusetts Compositions and methods for transient delivery of nucleases
HK1250038A1 (zh) 2015-03-19 2018-11-23 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
EP3274453B1 (en) * 2015-03-26 2021-01-27 Editas Medicine, Inc. Crispr/cas-mediated gene conversion
ES2959608T3 (es) 2015-04-03 2024-02-27 Dana Farber Cancer Inst Inc Composición y métodos de edición del genoma de células B
CA3021949C (en) 2015-04-24 2023-10-17 University Of Massachusetts Modified aav constructs and uses thereof
WO2016176652A2 (en) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
DK3289076T3 (da) 2015-05-01 2022-01-17 Prec Biosciences Inc Præcis sletning af kromosomale sekvenser in vivo
US11845928B2 (en) 2015-05-04 2023-12-19 Tsinghua University Methods and kits for fragmenting DNA
CN108136047B (zh) 2015-05-13 2022-12-13 西雅图儿童医院(Dba西雅图儿童研究所) 提高原代细胞中基于核酸内切酶的基因编辑
EP3316676A4 (en) 2015-06-30 2018-12-12 Regents of the University of Minnesota Haploid inducer line for accelerated genome editing
AU2016297167A1 (en) 2015-07-23 2018-02-22 Mayo Foundation For Medical Education And Research Editing mitochondrial DNA
JP6713691B2 (ja) * 2015-08-20 2020-07-01 大学共同利用機関法人情報・システム研究機構 動物細胞ゲノム部位特異的外来dna挿入方法及び前記挿入方法を用いて得られる細胞
US10837024B2 (en) 2015-09-17 2020-11-17 Cellectis Modifying messenger RNA stability in plant transformations
WO2017070525A1 (en) 2015-10-22 2017-04-27 University Of Massachusetts Methods and compositions for treating metabolic imbalance in neurodegenerative disease
US11426469B2 (en) 2015-10-22 2022-08-30 University Of Massachusetts Prostate-targeting adeno-associated virus serotype vectors
WO2017079428A1 (en) 2015-11-04 2017-05-11 President And Fellows Of Harvard College Site specific germline modification
MX2018007519A (es) 2015-12-18 2019-09-04 Sangamo Therapeutics Inc Alteracion dirigida del receptor celular del complejo mayor de histocompatibilidad (mhc).
WO2017106528A2 (en) 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Targeted disruption of the t cell receptor
MX2018008344A (es) 2016-01-11 2018-12-06 Univ Leland Stanford Junior Proteinas quimericas y metodos para regular la expresion genica.
JP7012645B2 (ja) 2016-01-11 2022-01-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー キメラタンパク質および免疫治療の方法
WO2017134601A1 (en) 2016-02-02 2017-08-10 Cellectis Modifying soybean oil composition through targeted knockout of the fad3a/b/c genes
EP3411059A4 (en) 2016-02-02 2019-10-16 University Of Massachusetts METHOD FOR INCREASING THE EFFECTIVENESS OF THE SYSTEMIC DELIVERY OF AVV GENES TO THE CENTRAL NERVOUS SYSTEM
EP3413928B1 (en) 2016-02-12 2022-04-20 University of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
WO2017144630A1 (en) 2016-02-26 2017-08-31 Cellectis Micelle based system nuclease encapsulation for in-vivo gene editing
US11340233B2 (en) 2016-03-07 2022-05-24 Pierre Fabre Medicament Universal method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
US11207426B2 (en) 2016-04-05 2021-12-28 University Of Massachusetts Compositions and methods for selective inhibition of grainyhead-like protein expression
EP3443080B1 (en) * 2016-04-13 2021-08-11 University of Massachusetts Repairing compound heterozygous recessive mutations by allele exchange
WO2017181105A1 (en) 2016-04-15 2017-10-19 University Of Massachusetts Methods and compositions for treating metabolic imbalance
EP4019628A1 (en) 2016-05-03 2022-06-29 Precision Biosciences, Inc. Engineered nucleases useful for treatment of hemophilia a
US11293033B2 (en) 2016-05-18 2022-04-05 Amyris, Inc. Compositions and methods for genomic integration of nucleic acids into exogenous landing pads
CN109415737A (zh) 2016-05-25 2019-03-01 嘉吉公司 用于在植物中产生突变的工程化核酸酶
EA201892624A1 (ru) 2016-05-26 2019-06-28 Нунхемс Б.В. Растения, дающие бессемянные плоды
SI3462853T1 (sl) 2016-06-03 2023-05-31 Regeneron Pharmaceuticals, Inc. Glodavci, ki izražajo eksogeno terminalno deoksinukleotidiltransferazo
WO2017218852A1 (en) 2016-06-15 2017-12-21 University Of Massachusetts Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
CA3029271A1 (en) 2016-06-28 2018-01-04 Cellectis Altering expression of gene products in plants through targeted insertion of nucleic acid sequences
WO2018007263A1 (en) 2016-07-06 2018-01-11 Cellectis Sequential gene editing in primary immune cells
EP3500696A4 (en) * 2016-08-16 2020-04-08 Bluebird Bio, Inc. VARIANTS OF IL-10 ALPHA RECEPTOR HOMING ENDONUCLEASE, COMPOSITIONS AND METHODS OF USE
CA3034271A1 (en) 2016-08-18 2018-02-22 Cellectis Black-spot resistant potatoes with reduced tuber-specific polyphenol oxidase activity
SG11201901364VA (en) 2016-08-24 2019-03-28 Sangamo Therapeutics Inc Engineered target specific nucleases
US20200002709A1 (en) 2016-09-01 2020-01-02 Cellectis Methods for altering amino acid content in plants
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
US20190225974A1 (en) 2016-09-23 2019-07-25 BASF Agricultural Solutions Seed US LLC Targeted genome optimization in plants
EP3516044B1 (en) 2016-09-23 2025-04-16 Fred Hutchinson Cancer Center Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
US11578340B2 (en) 2016-10-13 2023-02-14 University Of Massachusetts AAV capsid designs
WO2018073391A1 (en) 2016-10-19 2018-04-26 Cellectis Targeted gene insertion for improved immune cells therapy
WO2018092072A1 (en) 2016-11-16 2018-05-24 Cellectis Methods for altering amino acid content in plants through frameshift mutations
US11192929B2 (en) 2016-12-08 2021-12-07 Regents Of The University Of Minnesota Site-specific DNA base editing using modified APOBEC enzymes
WO2018115189A1 (en) 2016-12-21 2018-06-28 Cellectis Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
SG10202109874VA (en) 2017-01-19 2021-10-28 Open Monoclonal Tech Inc Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
JP7037577B2 (ja) 2017-03-15 2022-03-16 フレッド ハッチンソン キャンサー リサーチ センター 高親和性mage-a1特異的tcr及びその使用
US11767512B2 (en) 2017-04-13 2023-09-26 Cellectis Sequence specific reagents targeting CCR5 in primary hematopoietic cells
EP3392339A1 (en) 2017-04-18 2018-10-24 Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen Improved genome editing in plant cells
MX2019012452A (es) * 2017-04-21 2020-08-03 Prec Biosciences Inc Meganucleasas diseñadas especificas para secuencias de reconocimiento en el gen pcsk9.
CA3060622A1 (en) 2017-04-25 2018-11-01 Cellectis Alfalfa with reduced lignin composition
WO2018200943A1 (en) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
CA3059793A1 (en) 2017-05-03 2018-11-08 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene
EP3622073A4 (en) 2017-05-09 2021-01-06 University of Massachusetts METHOD FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
WO2018206791A1 (en) 2017-05-12 2018-11-15 Cellectis Protease based switch chimeric antigen receptors for safer cell immunotherapy
CA3064000A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
KR102742817B1 (ko) 2017-05-25 2024-12-17 리제너론 파마슈티칼스 인코포레이티드 Cblb 엔도뉴클레아제 변이체, 조성물 및 사용 방법
EP3641785A1 (en) 2017-06-19 2020-04-29 Cellectis Anti-hbv combination therapies involving specific endonucleases
US11332749B2 (en) 2017-07-13 2022-05-17 Regents Of The University Of Minnesota Real-time reporter systems for monitoring base editing
WO2019016360A1 (en) 2017-07-21 2019-01-24 Cellectis MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
JP2020533962A (ja) 2017-08-11 2020-11-26 フレッド ハッチンソン キャンサー リサーチ センター Braf特異的tcrおよびその使用
CA3071661A1 (en) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center Strep-tag specific chimeric receptors and uses thereof
EP3678690A1 (en) 2017-09-06 2020-07-15 Fred Hutchinson Cancer Research Center Methods for improving adoptive cell therapy
JP7397488B2 (ja) 2017-09-22 2023-12-13 ユニバーシティ オブ マサチューセッツ Sod1二重発現ベクターおよびその使用
CN111511903B (zh) 2017-10-19 2024-10-11 塞勒克提斯公司 用于改善的免疫细胞疗法的nk抑制剂基因的靶向基因整合
US20210069241A1 (en) 2017-10-20 2021-03-11 Fred Hutchinson Cancer Research Center Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
WO2019089913A1 (en) * 2017-11-01 2019-05-09 Precision Biosciences, Inc. Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a
WO2019109047A1 (en) 2017-12-01 2019-06-06 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
WO2019106163A1 (en) 2017-12-01 2019-06-06 Cellectis Reprogramming of genetically engineered primary immune cells
US11046758B2 (en) 2017-12-05 2021-06-29 Progastrine Et Cancers S.À R.L. Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
WO2019129850A1 (en) 2017-12-29 2019-07-04 Cellectis Off-the-shelf engineered cells for therapy
WO2019140278A1 (en) 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunotherapy targeting core binding factor antigens
US20200362366A1 (en) 2018-01-12 2020-11-19 Basf Se Gene underlying the number of spikelets per spike qtl in wheat on chromosome 7a
WO2019165116A1 (en) 2018-02-26 2019-08-29 Fred Hutchinson Cancer Research Center Compositions and methods for cellular immunotherapy
EP3759492A1 (en) 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin as a biomarker for immunotherapy
EP3781677A4 (en) 2018-04-16 2022-01-19 University of Massachusetts COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITTING
US12012607B2 (en) 2018-05-02 2024-06-18 Cellectis Engineering wheat with increased dietary fiber
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
WO2019234750A1 (en) 2018-06-07 2019-12-12 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Methods of regenerating and transforming cannabis
EP3802839A1 (en) 2018-06-07 2021-04-14 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Nucleic acid constructs and methods of using same
US12163129B2 (en) 2018-06-08 2024-12-10 University Of Massachusetts Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
US12060419B2 (en) 2018-06-14 2024-08-13 Regeneron Pharmaceuticals, Inc. CD79A chimeric antigen receptors
EP3806619A1 (en) 2018-06-15 2021-04-21 Nunhems B.V. Seedless watermelon plants comprising modifications in an abc transporter gene
CA3105331A1 (en) 2018-07-09 2020-01-16 Cellectis Canola with high oleic acid
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
MA53160A (fr) 2018-07-20 2021-05-26 Pf Medicament Récepteur pour vista
MX2021001938A (es) 2018-08-22 2021-04-19 Fred Hutchinson Cancer Center Inmunoterapia dirigida a antigenos kras o her2.
EP3844266A1 (en) 2018-08-28 2021-07-07 Fred Hutchinson Cancer Research Center Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
AU2019344927A1 (en) 2018-09-18 2021-04-01 Sangamo Therapeutics, Inc. Programmed cell death 1 (PD1) specific nucleases
EP4613367A1 (en) 2018-09-21 2025-09-10 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
WO2020068702A1 (en) 2018-09-24 2020-04-02 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
AU2019350466A1 (en) 2018-09-28 2021-04-29 Pierre Fabre Medicament New immunocytokines for the treatment of cancer
WO2020072059A1 (en) 2018-10-04 2020-04-09 Bluebird Bio, Inc. Cblb endonuclease variants, compositions, and methods of use
EP3877404A2 (en) 2018-11-09 2021-09-15 Fred Hutchinson Cancer Research Center T cell receptors specific for mesothelin and their use in immunotherapy
EP3906309A2 (en) 2019-01-04 2021-11-10 Cargill, Incorporated Engineered nucleases to generate mutations in plants
CA3125485A1 (en) 2019-01-11 2020-07-16 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
CN114026116A (zh) 2019-02-20 2022-02-08 弗雷德哈钦森癌症研究中心 Ras新抗原特异性结合蛋白及其用途
EP3935156A4 (en) 2019-03-07 2022-12-28 The Regents of The University of California CRISPR-CAS EFFECTIVE POLYPEPTIDES AND METHODS OF USE THEREOF
BR112021017703A8 (pt) 2019-03-11 2023-04-18 Hutchinson Fred Cancer Res Receptores de células t wt1 de alta avidez e usos dos mesmos
CN114258398A (zh) 2019-06-13 2022-03-29 总医院公司 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
EP3987024A4 (en) 2019-06-20 2023-11-01 University Of Massachusetts COMPOSITIONS AND METHODS FOR ENHANCED GENOMIC EDITING
US20220409661A1 (en) 2019-08-20 2022-12-29 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for wt-1
CA3150807A1 (en) 2019-09-04 2021-03-11 Y-Biologics Inc. Anti-vsig4 antibody or antigen binding fragment and uses thereof
BR112022005051A2 (pt) 2019-09-20 2022-06-21 Calyxt Inc Planta de soja, parte de planta ou célula de planta e método de produção
WO2021108248A1 (en) 2019-11-27 2021-06-03 Calyxt, Inc. Tal-effector nucleases for gene editing
US20230227559A1 (en) 2019-12-10 2023-07-20 Institut Pasteur New antibody blocking human fcgriiia and fcgriiib
WO2021130250A1 (en) 2019-12-23 2021-07-01 Cellectis New mesothelin specific chimeric antigen receptors (car) for solid tumors cancer immunotherapy
US20230046668A1 (en) 2019-12-24 2023-02-16 Selexis S.A. Targeted integration in mammalian sequences enhancing gene expression
JP2023519087A (ja) 2020-01-31 2023-05-10 カリックス インコーポレイテッド ダイズにおける飽和脂肪の増加
EP3889183A1 (en) 2020-04-01 2021-10-06 Pierre Fabre Medicament A protein complex comprising an immunocytokine
EP4146284A1 (en) 2020-05-06 2023-03-15 Cellectis S.A. Methods to genetically modify cells for delivery of therapeutic proteins
CA3177093A1 (en) 2020-05-06 2021-11-11 Cellectis S.A. Methods for targeted insertion of exogenous sequences in cellular genomes
DK4182297T3 (da) 2020-07-16 2025-12-01 Acuitas Therapeutics Inc Kationiske lipider til brug i lipid-nanopartikler
US20230242900A1 (en) * 2020-07-16 2023-08-03 The Texas A&M University System Self-eliminating transgenes
US20230248825A1 (en) 2020-07-24 2023-08-10 Cellectis S.A. T-cells expressing immune cell engagers in allogenic settings
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
AU2021329403A1 (en) * 2020-08-21 2023-05-04 Precision Biosciences, Inc. Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene
US12152251B2 (en) 2020-08-25 2024-11-26 Kite Pharma, Inc. T cells with improved functionality
JP2023542528A (ja) 2020-09-24 2023-10-10 フレッド ハッチンソン キャンサー センター Sox2抗原を標的とする免疫療法
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
CA3191387A1 (en) 2020-09-30 2022-04-07 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
TW202222841A (zh) 2020-10-06 2022-06-16 福瑞德哈金森腫瘤研究中心 用於治療表現mage-a1之疾病的組成物及方法
US20230416786A1 (en) 2020-11-30 2023-12-28 Cellectis Sa Use of aminoquinoline compounds for higher gene integration
US20250032540A1 (en) 2020-12-14 2025-01-30 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
JP2024505201A (ja) * 2021-01-25 2024-02-05 フレッド ハッチンソン キャンサー センター メガヌクレアーゼを使用したhsv-1の治療
JP2024506316A (ja) 2021-02-09 2024-02-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア リベリバクター属種によって引き起こされる植物の病気に対する防御に関与する免疫調節因子
WO2022184853A1 (en) 2021-03-03 2022-09-09 Pierre Fabre Medicament Anti-vsig4 antibody or antigen binding fragment and uses thereof
CA3212351A1 (en) 2021-03-12 2022-09-15 Mendus B.V. Methods of vaccination and use of cd47 blockade
AU2022267804A1 (en) 2021-04-30 2023-12-14 Cellectis S.A. New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy
WO2022229469A1 (en) 2021-04-30 2022-11-03 Pierre Fabre Medicament New stable anti-vista antibody
WO2022243529A1 (en) 2021-05-20 2022-11-24 Cellectis S.A. GENE THERAPY FOR THE TREATMENT OF HYPER-IgE SYNDROME (HIES) BY TARGETED GENE INTEGRATION
US20240318154A1 (en) 2021-05-20 2024-09-26 Cellectis Gene therapy for the treatment of severe combined immunodeficiency (scid) related to rag1
AU2022277649A1 (en) 2021-05-21 2023-11-30 Cellectis S.A. Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
WO2022272296A2 (en) 2021-06-25 2022-12-29 Homology Medicines, Inc. Adeno-associated virus packaging systems
TW202317602A (zh) 2021-07-15 2023-05-01 福瑞德哈金森腫瘤中心 嵌合多肽
IL310550A (en) 2021-08-04 2024-03-01 Univ Colorado Regents LAT-activating chimeric antigen receptor T cells and methods of using them
US20230076072A1 (en) 2021-08-24 2023-03-09 Oxford Biomedica Solutions Llc Adeno-associated virus formulations
WO2023077086A1 (en) 2021-10-29 2023-05-04 Homology Medicines, Inc. Methods and compositions for the purification of adeno-associated virus
CA3237482A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
GB202117314D0 (en) 2021-11-30 2022-01-12 Clarke David John Cyclic nucleic acid fragmentation
US20250223584A2 (en) 2021-12-03 2025-07-10 The Broad Institute, Inc. Compositions and methods for efficient in vivo delivery
WO2023114901A2 (en) 2021-12-15 2023-06-22 Oxford Biomedica Solutions Llc Methods and compositions for the production of adeno-associated virus
WO2023114943A2 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023213814A1 (en) 2022-05-02 2023-11-09 Pierre Fabre Medicament New formulation of anti vista antibody
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
EP4276174A1 (en) 2022-05-09 2023-11-15 Cellectis S.A. Gene therapy for the treatment of activated pi3kinase delta syndrome type 1 (apds1)
EP4526459A2 (en) 2022-05-17 2025-03-26 Nvelop Therapeutics, Inc. Compositions and methods for efficient in vivo delivery
WO2023233003A1 (en) 2022-06-03 2023-12-07 Cellectis Sa Tale base editors for gene and cell therapy
AU2023298102A1 (en) 2022-06-30 2024-11-14 Cellectis S.A. Enhancing safety of t-cell-mediated immunotherapy
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
JP2025536578A (ja) 2022-11-03 2025-11-07 セレクティス ソシエテ アノニム T細胞媒介免疫療法の有効性及び安全性の増進
WO2024121380A1 (en) 2022-12-08 2024-06-13 Pierre Fabre Medicament Vaccinal composition and adjuvant
EP4688830A1 (en) 2023-04-07 2026-02-11 Commissariat à l'Energie Atomique et aux Energies Alternatives Use of antibody against the endothelin receptor b for diagnostic and therapeutic applications
EP4713453A1 (en) 2023-05-15 2026-03-25 nChroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2024236547A1 (en) 2023-05-18 2024-11-21 Inceptor Bio, Llc Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof
WO2024246301A1 (en) 2023-06-02 2024-12-05 Cellectis Sa Methods for identifying tale base editors off-sites
WO2025046513A1 (en) 2023-08-29 2025-03-06 Inceptor Bio, Llc Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof
WO2025054540A1 (en) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Methods of gene-editing using programmable nucleases
WO2025059215A1 (en) 2023-09-12 2025-03-20 Aadigen, Llc Methods and compositions for treating or preventing cancer
WO2025081123A1 (en) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Methods and compositions for improving t cell immunotherapy
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload
WO2025262278A1 (en) 2024-06-21 2025-12-26 Institut Pasteur A neurovita short interfering peptide suitable for neuroprotection and neuroregeneration and uses thereof
WO2025262307A2 (en) 2024-06-21 2025-12-26 Institut Pasteur Vhh suitable to vectorize molecules intracellularly
WO2026047626A1 (en) 2024-08-30 2026-03-05 Inceptor Bio, Llc Compositions and methods involving immune cells engineered for binding bispecific antibodies for use in cell therapy

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5006333A (en) 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
FR2646438B1 (fr) * 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2084307A1 (en) 1990-06-01 1991-12-02 Cetus Oncology Corporation Compositions and methods for identifying biologically active molecules
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US6063630A (en) * 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
WO1993020207A1 (en) 1992-04-02 1993-10-14 The United States Of America, As Represented By The Secretary Of Health And Human Services Use of restriction endonucleases against viruses, including hiv
US5436150A (en) * 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US20040019916A1 (en) * 1992-04-24 2004-01-29 Zarling David A. In vivo homologous sequence targeting in eukaryotic cells
US6395959B1 (en) * 1992-05-05 2002-05-28 Institut Pasteur Nucleotide sequence encoding the enzyme I SceI and the use thereof
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5474896A (en) * 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US20040054156A1 (en) * 1992-05-14 2004-03-18 Kenneth Draper Method and reagent for inhibiting hepatitis B viral replication
ATE513037T1 (de) 1993-02-12 2011-07-15 Univ Johns Hopkins Funktionelle domänen der restriktionsendonukleasen aus flavobakterium okeanokoites (foki)
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US6265196B1 (en) 1996-05-07 2001-07-24 Johns Hopkins University Methods for inactivating target DNA and for detecting conformational change in a nucleic acid
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
IL120241A0 (en) * 1997-02-17 1997-06-10 B G Negev Technologies And App DNA segments encoding a domain of ho-endonuclease
US6232112B1 (en) 1997-11-24 2001-05-15 Flinders Technologies Pty Ltd Of Flinders University Reagents and methods for diversification of DNA
EP1147209A2 (en) 1999-02-03 2001-10-24 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
CA2360878A1 (en) 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving excision of targeting dna
JP2002541822A (ja) * 1999-04-14 2002-12-10 エム ユー エス シー ファンデーション フォー リサーチ ディベロップメント 組織特異的および病原体特異的毒性物質ならびにリボザイム
EP1272626A2 (en) 2000-03-21 2003-01-08 Neugenesis Corporation Methods for in vivo diversification of single genes
US20020187484A1 (en) 2000-11-27 2002-12-12 Jon Thorson Molecular break lights probes for detecting nucleotide cleavage
GB0029375D0 (en) 2000-12-01 2001-01-17 Total Fina Elf Substrate linked directed evolution (slide)
AU2001297625A1 (en) * 2000-12-21 2002-09-12 Bristol-Myers Squibb Company Nucleic acid molecules and polypeptides for a human cation channel polypeptide
US7476500B1 (en) * 2001-03-19 2009-01-13 President And Fellows Of Harvard College In vivo selection system for enzyme activity
AU2002317771A1 (en) 2001-06-05 2002-12-16 Cellectis Methods for modifying the cpg content of polynucleotides
DE10131786A1 (de) * 2001-07-04 2003-01-16 Sungene Gmbh & Co Kgaa Rekombinationssysteme und Verfahren zum Entfernen von Nukleinsäuresequenzen aus dem Genom eukaryotischer Organismen
AU2002353934A1 (en) * 2001-10-31 2003-05-12 Oxford Glycosciences (Uk) Ltd. Biomarkers of liver function
US7462758B2 (en) * 2001-12-20 2008-12-09 Sungene Gmbh & Co. Kgaa Methods for the transformation of vegetal plastids
US8206965B2 (en) * 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
WO2004067753A2 (en) * 2003-01-28 2004-08-12 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
US7888121B2 (en) * 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP1591521A1 (en) 2004-04-30 2005-11-02 Cellectis I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
ES2347684T3 (es) 2005-03-15 2010-11-03 Cellectis Variantes de la meganucleasa i-crei con especificidad modifica, metodo de preparacion y usos de las mismas.
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
CA2626262C (en) * 2005-10-18 2015-09-08 Homme W. Hellinga Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
WO2007049095A1 (en) 2005-10-25 2007-05-03 Cellectis Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof
WO2007060495A1 (en) 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
WO2007093836A1 (en) 2006-02-13 2007-08-23 Cellectis Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof
RU2318466C1 (ru) 2006-06-23 2008-03-10 Давид Георгиевич Кочиев Лазерная установка для абляции тканей и литотрипсии
WO2008002199A2 (en) 2006-06-23 2008-01-03 Aichinger, Elena Biocidal and virulicidal agent-clathrate 1,6,3,8-dimethan-tetra-aza-cyclodecane-sodium carbonate
WO2008002274A1 (en) 2006-06-27 2008-01-03 Inventys Pte Ltd Method and system for client-side user interface enhancement to enable application integration and portalisation
WO2008010009A1 (en) 2006-07-18 2008-01-24 Cellectis Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof
BRPI0718747A2 (pt) 2006-11-14 2013-12-03 Cellectis Variantes meganuclease que clavam uma ou sequência alvo de dna a partir do gene hprt e usos das mesmas.
WO2009001159A1 (en) 2007-06-25 2008-12-31 Cellectis Method for enhancing the cleavage activity of i-crei derived meganucleases
WO2008059317A1 (en) 2006-11-14 2008-05-22 Cellectis Meganuclease variants cleaving a dna target sequence from the hprt gene and uses thereof
WO2008093152A1 (en) 2007-02-01 2008-08-07 Cellectis Obligate heterodimer meganucleases and uses thereof
WO2008149176A1 (en) 2007-06-06 2008-12-11 Cellectis Meganuclease variants cleaving a dna target sequence from the mouse rosa26 locus and uses thereof
CN101784658A (zh) 2007-06-06 2010-07-21 赛莱克蒂斯公司 增强来自I-CreI的大范围核酸酶的切割活性的方法
WO2009013559A1 (en) 2007-07-23 2009-01-29 Cellectis Meganuclease variants cleaving a dna target sequence from the human hemoglobin beta gene and uses thereof
WO2009019528A1 (en) 2007-08-03 2009-02-12 Cellectis Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof
EP2023541B1 (en) 2007-08-07 2013-02-13 Nokia Siemens Networks Oy Method, device and communication system to avoid loops in an Ethernet Ring System with an underlying 802.3ad network

Similar Documents

Publication Publication Date Title
JP2006518372A5 (enExample)
JP2016501532A5 (enExample)
Hryhorowicz et al. CRISPR/Cas9 immune system as a tool for genome engineering
JP7210029B2 (ja) CRISPR-Cas9の阻害因子
IL293526A (en) Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications
JP2019115348A5 (enExample)
JP2018534950A5 (enExample)
EP3611258A1 (en) System and method for genome editing
JP2017018125A5 (enExample)
JP2016520320A5 (enExample)
JP2016504026A5 (enExample)
JP2016535594A (ja) 高反復モチーフを備えたdna配列を効率的かつ特異的に標的とするレアカットエンドヌクレアーゼの設計
JP2018183180A5 (enExample)
FI3352776T3 (fi) Htt-repressoreita ja niiden käyttötapoja
JP2011514144A5 (enExample)
JP2018520997A5 (enExample)
RU2016101198A (ru) Доставка, применение и применения в терапии систем crispr-cas и композиций для целенаправленного воздействия на нарушения и заболевания с использованием вирусных компонентов
JP2016521995A5 (enExample)
JP2018522563A5 (enExample)
JP2016526885A5 (enExample)
CN108350454A (zh) 等位基因选择性基因编辑及其用途
FI3546585T3 (fi) Muokatun intronin käsittäviä nukleiinihappoja käytettäviksi hyperbilirubinemian hoidossa
JP2016503655A5 (enExample)
JP2016500262A5 (enExample)
JP2014513952A5 (enExample)